E2F transcription factor 1 mRNA 3' untranslated region (E2F1 mRNA 3'UTR)

The E2F transcription factor 1 (E2F1) mRNA 3' untranslated region (3'UTR) is a pivotal regulatory segment of the E2F1 transcript that governs protein expression through post-transcriptional mechanisms (NIH: PMC3071055). It serves as a docking site for numerous microRNAs (miRNAs), including the miR-17-92 cluster, miR-205, and miR-1258, which typically suppress E2F1 translation or promote mRNA decay to regulate the cell cycle (PubMed: 33614415, NIH: PMC3426374). Furthermore, RNA-binding proteins such as RALY and IGF2BP1 bind to this region to stabilize the transcript, often influenced by m6A methylation (Frontiers in Oncology, 2023; Int J Biol Sci, 2022). Dysregulation of these 3'UTR interactions—due to miRNA downregulation or genetic mutations—is a common feature in malignancies like melanoma, glioma, and colorectal cancer, where it leads to E2F1 overexpression and subsequent uncontrolled cell proliferation (NIH: PMC6691155). Therapeutic interventions targeting the E2F1 mRNA 3'UTR, such as miRNA mimics and antisense oligonucleotides (ASOs), are being developed to restore regulatory control and inhibit tumor growth (PubMed: 24959757). These RNA-targeted strategies offer a means to modulate E2F1 activity more specifically than traditional small molecule inhibitors, though they face challenges regarding delivery and off-target effects.

Other names

E2F1 3'UTRE2F1 3'-untranslated regionE2F1 mRNA 3-prime UTR

MicroRNA-mediated translational repression and mRNA degradation; antisense oligonucleotide-mediated gene silencing.